FeesSafety
Pluang+

Kura Oncology and Kyowa Kirin to present first clinical data on ziftomenib-FLT3 inhibitor combos at ASH 2026

Market News
04 Nov 2026, 16:02 WIB
GlobeNewsWire
View Source
Bullish
Kura Oncology and Kyowa Kirin to present first clinical data on ziftomenib-FLT3 inhibitor combos at ASH 2026

Kura Oncology and Kyowa Kirin will present initial clinical data on ziftomenib combined with FLT3 inhibitors quizartinib and gilteritinib for acute myeloid leukemia (AML) at the ASH 2026 meeting. The data includes early safety and efficacy results in newly diagnosed and relapsed/refractory NPM1/FLT3 co-mutated AML patients, supporting ongoing Phase 3 trials. Additional presentations will cover longer-term results of ziftomenib with venetoclax and azacitidine, and exploratory analyses of ziftomenib’s activity in other AML subtypes. These findings aim to establish ziftomenib as a key treatment option across AML stages and combinations.

Kura Oncology and Kyowa Kirin's upcoming presentation on ziftomenib-FLT3 inhibitor clinical data provides context for health sector trading activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 20:41 WIB: Out of 150 priced health-sector US stocks, 127 rose and 19 fell today. Notable movers include CVS Health Corp at USD 86.90 with a 4.93% decline and 91% buy order activity, Tilray Brands Inc at USD 2.78 with a 4.91% gain but 96% sell order activity, and Alcon AG at USD 75.51 with a 4.34% gain and 91% sell order activity.

More News

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment named Leader by Everest Group for US IT staffing and consulting excellence

Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...

Market News
Bullish
28 minutes ago
Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma to present at multiple investor conferences in November and December 2026

Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...

Market News
Neutral
1 hour ago
etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro acquires Argentine fintech LB Finanzas to expand in Latin America

etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...

Company Fundamentals
Bullish
1 hour ago
JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com to release Q3 2026 financial results on Nov 17 with a management call scheduled.

JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...

Company Fundamentals
Neutral
4 hours ago
KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings to release Q3 2026 financial results on Nov 16 with a live earnings call.

KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App